Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence.
| Autor: | Avoranta ST; Department of Oncology and Radiotherapy, University of Turku and Turku University Hospital, FIN-20521 Turku, Finland. stavor@utu.fi, Korkeila EA, Syrjänen KJ, Pyrhönen SO, Sundström JT |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of gastroenterology [World J Gastroenterol] 2012 Sep 07; Vol. 18 (33), pp. 4549-56. |
| DOI: | 10.3748/wjg.v18.i33.4549 |
| Abstrakt: | Aim: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. Methods: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radiotherapy (RT, n = 90), long-course (chemo) RT (n = 53) or surgery alone (n = 71) were studied with immunohistochemistry for CD44v6. The extent and intensity of membranous and cytoplasmic CD44v6 staining, and the intratumoral membranous staining pattern, were analyzed. Results: Membranous CD44v6 expression was seen in 84% and cytoplasmic expression in 81% of the cases. In 59% of the tumors with membranous CD44v6 expression, the staining pattern in the invasive front was determined as "front-positive" and in 41% as "front-negative". The latter pattern was associated with narrower circumferential margin (P = 0.01), infiltrative growth pattern (P < 0.001), and shorter disease-free survival in univariate survival analysis (P = 0.022) when compared to the "front-positive" tumors. Conclusion: The lack of membranous CD44v6 in the rectal cancer invasive front could be used as a method to identify patients at increased risk for recurrent disease. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|